Order Article Reprints

Yasutomi E, Hiraoka S, Yamamoto S, Oka S, Hirai M, Yamasaki Y, Inokuchi T, Kinugasa H, Takahara M, Harada K, et al. Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents. Journal of Clinical Medicine. 2019; 8(12):2109. https://doi.org/10.3390/jcm8122109

Yasutomi, Eriko, Sakiko Hiraoka, Shumpei Yamamoto, Shohei Oka, Mami Hirai, Yasushi Yamasaki, Toshihiro Inokuchi, Hideaki Kinugasa, Masahiro Takahara, Keita Harada, and et al. 2019. "Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents" Journal of Clinical Medicine 8, no. 12: 2109. https://doi.org/10.3390/jcm8122109

Yasutomi, E., Hiraoka, S., Yamamoto, S., Oka, S., Hirai, M., Yamasaki, Y., Inokuchi, T., Kinugasa, H., Takahara, M., Harada, K., Kato, J., & Okada, H. (2019). Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents. Journal of Clinical Medicine, 8(12), 2109. https://doi.org/10.3390/jcm8122109